Common adverse reactions The most common side effects (≥20% of patients) listed in the prescribing information include:1 Low red blood cell count (anemia) Tiredness Bleeding Fever with low white blood cell count Muscle pain Nausea Swelling of arms or legs Low platelet count Shortness of breath Decreased appetite Changes in taste Pain or sores in your mouth or throat Constipation Rash Serious adverse reactions The serious adverse reactions listed in the prescribing information include:1 Changes in the electrical activity of your heart called QTc prolongation Use in a specific population Warning: Daurismo (glasdegib) can cause embryo-fetal death or severe birth defects when given to a pregnant woman.1 Talk to your doctor if you become pregnant during treatment or think you may be pregnant. Females who are able to become pregnant should use effective birth control (contraception) during treatment and for at least 30 days after the last dose. Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment and for at least 4 months after the last dose.1 It is advised not breastfeed during treatment and for at least 30 days after the last dose.1 Before starting with treatment, tell your doctor about all of the medicines you take and about all the medical conditions you have, including if you: Have heart problems including a condition called long QT syndrome Have abnormal blood salt (electrolytes) levels For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.1 References 1. Full prescribing information [FDA]: Daurismo (glasdegib) [PDF] Pfizer, Nov 2018 2. Daurismo Patient Brochure Pfizer, cited Sep 2021 3. FDA approves new treatment for patients with acute myeloid leukemia FDA, Nov 2018 4. Daurismo EMA Jun 2020 5. Health Canada Approval of Daurismo (glasdegib) Pfizer, Jun 2020